Pancreatic Cancer Clinical Trials in Los Angeles

Showing 81-100 of 127 trials

Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia

NCT03207724

This study is being conducted to examine the safety of the investigational drug, Xilonix(™), in addition to standard doses of Onivyde® (nanoliposomal irinotecan) and 5- fluorouracil (5FU)/folinic acid (leucovorin) for pancreatic cancer patients with cachexia. Cachexia is a syndrome that includes involuntary weight loss and physical deterioration that can contribute to poor outcomes of cancer treatment. In other studies, Xilonix has increased lean body mass in advanced cancer patients. This increase could lead to improved weight maintenance and quality of life.

Pancreatic CancerCachexiaWeight Loss

Andrew Hendifar, MD16 participantsStarted Oct 2017

Los Angeles, California, United States

COMPLETEDPhase 3< 1 mile

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

NCT02923921

To compare the efficacy of pegilodecakin in combination with FOLFOX versus FOLFOX alone in participants with metastatic pancreatic cancer as measured by overall survival.

Pancreatic Cancer

Eli Lilly and Company567 participantsStarted Mar 2017

Gilbert, Arizona, United States • Goodyear, Arizona, United States • Phoenix, Arizona, United States +127 more locations

Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

Pancreatic Cancer Trials in Other Cities

AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer

Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer

Vaccine Study for Surgically Resected Pancreatic Cancer

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers

Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer

Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma

High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer

Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Other Conditions in Los Angeles